Physician profile
Charles A Smith
NPI 1861498669
$2,253.70
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $444 · 2020: $475 · 2021: $230 · 2022: $557 · 2023: $547.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $547.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $547.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $396.16 | 2019-2023 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $332.90 | 2019-2023 | Farxiga |
| Abbvie INC. | $315.62 | 2021-2023 | Ubrelvy, Qulipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $201.02 | 2019-2023 | Synjardy, Jardiance, Glyxambi |
| Pfizer INC. | $166.44 | 2019-2023 | |
| Glaxosmithkline, LLC. | $140.16 | 2019-2022 | |
| Astellas Pharma US INC | $131.24 | 2019-2022 | |
| Amgen INC. | $124.86 | 2019-2023 | Otezla, Repatha, Prolia |
| Janssen Pharmaceuticals, INC | $61.95 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $56.15 | 2019-2021 | |
| Exact Sciences Corporation | $53.26 | 2023 | Cologuard Collection Kit |
| Esperion Therapeutics, INC. | $53.22 | 2020-2021 | |
| Amarin Pharma, INC. | $50.39 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $32.44 | 2022 | |
| Allergan, INC. | $30.24 | 2019-2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $25.84 | 2019 | |
| Ibsa Pharma INC. | $21.85 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $17.39 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.23 | 2019 | |
| Daiichi Sankyo INC. | $14.64 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.70 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.